Table 3.

Adverse events and dose reduction of dacomitinib.

Adverse events	Any grade	Grade ≥ 3
Diarrhea	75 (49.0%)	3 (2.0%)
Paronychia	60 (39.2%)	0 (0.0%)
Dermatitis	45 (29.4%)	1 (0.7%)
Rash	78 (51.0%)	7 (4.6%)
Oral mucositis	62 (40.5%)	0 (0.0%)
Nausea	3 (2.0%)	0 (0.0%)
Fatigue	6 (3.9%)	0 (0.0%)
Increased AST/ALT	1 (0.7%)	0 (0.0%)
Pneumonitis	0 (0.0%)	0 (0.0%)
Final reduced dose owing to adverse events
No dose reduction	22 (14.4%)
Dose reduction	131 (85.6%)
30 mg per day	75 (49.0%)
15 mg per day	56 (36.6%)
Permanent discontinuation	13 (8.5%)
Temporary interruption	37 (24.2%)